Health Canada approves Novo Nordisk's obesity drug to reduce risk of non-fatal heart attack

Health Canada has approved Novo Nordisk's weight-loss drug Wegovy to reduce the risk of non-fatal heart attack, the drug maker says.

Novo Nordisk said Wednesday that Wegovy is the first Health Canada-approved treatment for both chronic weight management and to reduce the risk of non-fatal myocardial infarction.